Anteris Technologies Global (NASDAQ Uplisting/Dual Listing)(AVR)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

AVR Anteris Technologies Global (NASDAQ Uplisting/Dual Listing)

交易中 07-31 15:17:23 EDT

7.86

-0.38

-4.67%

最高8.39	最低7.85	成交量63.57万
今开8.27	昨收8.24	日振幅6.55%
总市值7.61亿	流通市值4.74亿	总股本9,685万
成交额505.75万	换手率1.05%	流通股本6,031万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"AVR","market":"US","secType":"STK","nameCN":"Anteris Technologies Global (NASDAQ Uplisting/Dual Listing)","latestPrice":7.855,"timestamp":1785525437946,"preClose":8.24,"halted":0,"volume":635733,"delay":0,"changeRate":-0.04672330097087376,"floatShares":60309900,"shares":96849700,"eps":-2.22,"marketStatus":"交易中","change":-0.385,"latestTime":"07-31 15:17:23 EDT","open":8.27,"high":8.39,"low":7.85,"amount":5057504.8408962,"amplitude":0.065534,"askPrice":7.86,"askSize":100,"bidPrice":7.85,"bidSize":1078,"shortable":3,"etf":0,"ttmEps":-2.22,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1785528000000},"marketStatusCode":2,"adr":0,"listingDate":1734066000000,"exchange":"NASDAQ","adjPreClose":8.24,"preHourTrading":{"tag":"盘前","latestPrice":8.33,"preClose":8.24,"latestTime":"09:28 EDT","volume":196,"amount":1650.829796,"timestamp":1785504507934,"change":0.09,"changeRate":0.010922,"amplitude":0.057039},"postHourTrading":{"tag":"盘后","latestPrice":8.4,"preClose":8.24,"latestTime":"19:38 EDT","volume":34090,"amount":280936.51,"timestamp":1785454731410,"change":0.16,"changeRate":0.019417,"amplitude":0.033495},"volumeRatio":0.690275,"impliedVol":0.6911,"impliedVolPercentile":0.2652},"requestUrl":"/m/hq/s/AVR","defaultTab":"news","newsList":[{"id":"1109848032","title":"Anteris Technologies Global 获法国监管批准，启动Duravr经导管心脏瓣膜全球试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1109848032","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109848032?lang=zh_cn&edition=full","pubTime":"2026-06-08 18:03","pubTimestamp":1780913027,"startTime":"0","endTime":"0","summary":"Anteris Technologies Global 宣布，其Duravr经导管心脏瓣膜的全球临床试验已获得法国监管机构的批准。这一关键性进展为该公司在美国纳斯达克双重上市后，推动其旗舰产品进入重要市场铺平了道路。法国监管的绿灯意味着试验可以在法国境内开展，标志着Duravr瓣膜在满足欧洲乃至全球严格监管标准方面迈出了坚实一步。该试验旨在评估该创新器械的安全性与有效性，有望为患有心脏瓣膜疾病的患者提供新的微创治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","AVR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157891008","title":"Anteris Technologies Global Corp 拟通过TD Cowen发行至多2.5亿美元普通股","url":"https://stock-news.laohu8.com/highlight/detail?id=1157891008","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157891008?lang=zh_cn&edition=full","pubTime":"2026-05-23 05:17","pubTimestamp":1779484630,"startTime":"0","endTime":"0","summary":"Anteris Technologies Global Corp计划通过TD Cowen作为承销商，发行至多2.5亿美元的普通股。此举已在美国证券交易委员会（SEC）提交的相关文件中披露。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","AVR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117443530","title":"Anteris Technologies Global Corp宣布终止与V2vmedtech协议下的开发投入","url":"https://stock-news.laohu8.com/highlight/detail?id=1117443530","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1117443530?lang=zh_cn&edition=full","pubTime":"2026-04-30 04:50","pubTimestamp":1777495816,"startTime":"0","endTime":"0","summary":"根据最新提交的美国证券交易委员会文件显示，Anteris Technologies Global Corp决定停止履行与V2vmedtech合作协议中约定的开发投入义务。这一重大调整标志着双方战略合作关系的重大转变。\n该决议立即生效，公司将重新评估相关医疗技术项目的资源分配方案。此次协议调整预计将对Anteris Technologies Global Corp未来季度的研发支出产生直接影响。\n市场分析师指出，这一决定可能源于公司战略重点的重新定位，或反映其寻求更高效研发路径的考量。投资者将密切关注后续发展，特别是公司是否会寻求新的合作伙伴来推进相关技术开发。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVR","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172929384","title":"Anteris Technologies Global Corp 达成重要里程碑 有望加速美国Paradigm试验基地启动","url":"https://stock-news.laohu8.com/highlight/detail?id=1172929384","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1172929384?lang=zh_cn&edition=full","pubTime":"2026-04-28 18:07","pubTimestamp":1777370841,"startTime":"0","endTime":"0","summary":"Anteris Technologies Global Corp（纳斯达克上市/双重上市）近日取得关键进展，这一里程碑事件预计将为该公司在美国启动Paradigm试验基地的筹备工作扫清障碍。\n该突破性进展标志着公司核心临床项目推进至新阶段。试验基地的顺利激活对后续患者入组及数据收集至关重要，有望为结构性心脏病创新疗法的开发注入强劲动力。\n市场观察人士指出，此次里程碑的达成不仅验证了公司的技术执行力，更为其在美国市场的战略布局奠定坚实基础。随着Paradigm试验步入正轨，公司商业化进程或将迎来加速期。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVR","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2502870517","title":"Anteris Technologies(AVR.US)获Lake Street首次覆盖，给予买入评级, 目标价20.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2502870517","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2502870517?lang=zh_cn&edition=full","pubTime":"2025-01-09 01:41","pubTimestamp":1736358102,"startTime":"0","endTime":"0","summary":"Anteris Technologies(AVR.US)获Lake Street首次覆盖，给予买入评级, 目标价20.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/01/09014147279955.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["AVR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179521583","title":"异动解读 | AVR首次公开募股后盘中暴跌12.33%,募资增股致短期供给压力","url":"https://stock-news.laohu8.com/highlight/detail?id=1179521583","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1179521583?lang=zh_cn&edition=full","pubTime":"2024-12-14 03:34","pubTimestamp":1734118456,"startTime":"0","endTime":"0","summary":"心脏瓣膜公司Anteris Technologies Global (AVR) 在纳斯达克上市首日当日暴跌12.33%,引发市场广泛关注。\nAVR当日在纳斯达克进行首次公开募股,发行价为每股6美元,共募集约8,900万美元资金。但开盘后股价即呈现大跌,盘中一度下探至5.26美元。\n市场分析认为,AVR首次公开募股增发新股导致股票供给激增,短期内形成供给压力拖累股价下跌,同时或有投机资金涌入、出货操作亦加剧了股价震荡。投资者对未来发展前景存在分歧,市场情绪转差致股价重挫。预计供需矛盾在未来将得到缓解,股价震荡将趋于平稳。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"异动解读 | AVR首次公开募股后盘中暴跌12.33%,募资增股致短期供给压力","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["AVR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2490065371","title":"澳大利亚医疗设备公司Anteris(AVR.US)IPO定价6.78美元/股 拟筹资1亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2490065371","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490065371?lang=zh_cn&edition=full","pubTime":"2024-12-10 15:45","pubTimestamp":1733816700,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，澳大利亚的人工心脏瓣膜制造商Anteris Technologies周一宣布了其 IPO 条款。该公司计划以每股6.78美元的价格发行1,480万股股票，以筹集1亿美元资金。按照拟议价格，Anteris Technologies的市值将达到2.44亿美元。该公司的股票目前在澳大利亚证券交易所上市，代码为“AVR”。Anteris是一家专注于主动脉狭窄患者的结构性心脏公司。Anteris于2024年2月14日秘密提交了申请。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1222675.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["AVR","159873"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.anteristech.com","stockEarnings":[{"period":"1week","weight":0.0061},{"period":"1month","weight":-0.1635},{"period":"3month","weight":0.2956},{"period":"6month","weight":0.3802},{"period":"1year","weight":1.4745},{"period":"ytd","weight":0.6513}],"compareEarnings":[{"period":"1week","weight":0.0048},{"period":"1month","weight":-0.0068},{"period":"3month","weight":0.0292},{"period":"6month","weight":0.0719},{"period":"1year","weight":0.169},{"period":"ytd","weight":0.0876}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Anteris Technologies Global Corp.于2024年1月29日在特拉华州注册成立。该公司是一家结构性心脏公司，致力于发现、开发和商业化创新医疗设备，旨在改善主动脉瓣狭窄患者的生活质量。","exchange":"NASDAQ","name":"Anteris Technologies Global (NASDAQ Uplisting/Dual Listing)","nameEN":"Anteris Technologies Global (NASDAQ Uplisting/Dual Listing)"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Anteris Technologies Global (NASDAQ Uplisting/Dual Listing)(AVR)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Anteris Technologies Global (NASDAQ Uplisting/Dual Listing)(AVR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Anteris Technologies Global (NASDAQ Uplisting/Dual Listing),AVR,Anteris Technologies Global (NASDAQ Uplisting/Dual Listing)股票,Anteris Technologies Global (NASDAQ Uplisting/Dual Listing)股票老虎,Anteris Technologies Global (NASDAQ Uplisting/Dual Listing)股票老虎国际,Anteris Technologies Global (NASDAQ Uplisting/Dual Listing)行情,Anteris Technologies Global (NASDAQ Uplisting/Dual Listing)股票行情,Anteris Technologies Global (NASDAQ Uplisting/Dual Listing)股价,Anteris Technologies Global (NASDAQ Uplisting/Dual Listing)股市,Anteris Technologies Global (NASDAQ Uplisting/Dual Listing)股票价格,Anteris Technologies Global (NASDAQ Uplisting/Dual Listing)股票交易,Anteris Technologies Global (NASDAQ Uplisting/Dual Listing)股票购买,Anteris Technologies Global (NASDAQ Uplisting/Dual Listing)股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Anteris Technologies Global (NASDAQ Uplisting/Dual Listing)(AVR)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Anteris Technologies Global (NASDAQ Uplisting/Dual Listing)(AVR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}